<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183155</url>
  </required_header>
  <id_info>
    <org_study_id>107.236</org_study_id>
    <nct_id>NCT02183155</nct_id>
  </id_info>
  <brief_title>Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects</brief_title>
  <official_title>A Double Blind, Randomized, Parallel Group Trial to Compare the Effect of Three Doses of Meloxicam Tablets (7.5, 15 and 30 mg) With Placebo on Bleeding Time in Healthy Subjects; With Extended-release Indomethacin Capsules 75 mg (Open-label) as an Active Control to Assess Trial Sensitivity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg&#xD;
      and 30 mg) with meloxicam placebo. Extended-release indomethacin capsules (75 mg) was an&#xD;
      active control to assess trial sensitivity on bleeding time in healthy subjects. The&#xD;
      secondary aim of this study was to assess effects of treatment on other platelet function and&#xD;
      coagulation parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in bleeding time</measure>
    <time_frame>up to 6 hours post-dose at day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in platelet aggregation</measure>
    <time_frame>up to 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Platelet thromboxane B2 synthesis (TXB2 synthesis)</measure>
    <time_frame>up to 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thromboplastin Time (PT)</measure>
    <time_frame>up to 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Activated Partial Thromboplastin Time (APTT)</measure>
    <time_frame>up to 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Platelet Count</measure>
    <time_frame>up to 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leucocyte Activation</measure>
    <time_frame>Day 1 and 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of meloxicam</measure>
    <time_frame>pre-dose, 3 and 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of indomethacin</measure>
    <time_frame>pre-dose, 3 and 6 hours post-dose at day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Meloxicam - low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam - medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam - high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended-release indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam - low</intervention_name>
    <arm_group_label>Meloxicam - low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam - medium</intervention_name>
    <arm_group_label>Meloxicam - medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam - high</intervention_name>
    <arm_group_label>Meloxicam - high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-release indomethacin</intervention_name>
    <arm_group_label>Extended-release indomethacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects between the ages of 18 and 55 years&#xD;
&#xD;
          -  Negative urine pregnancy test on Day1 for females of childbearing potential&#xD;
&#xD;
          -  Weight within +/- 20 percent of ideal weight according to the Metropolitan Life Height&#xD;
             and Weight chart&#xD;
&#xD;
          -  Willing and able to cooperate with the investigator and his/her staff&#xD;
&#xD;
          -  Written informed consent in accordance with GCP (Good Clinical Practice) and local&#xD;
             legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding, medical condition or dietary restriction that, in the investigator's&#xD;
             opinion, may interfere with optimal participation in the study or produce a&#xD;
             significant risk to the subject&#xD;
&#xD;
          -  In the opinion of the investigator, the subject has any disease or condition that may&#xD;
             result in altered absorption, excess accumulation, or impaired metabolism or excretion&#xD;
             of the trial medications&#xD;
&#xD;
          -  A known or suspected hypersensitivity to any of the trial medications or their&#xD;
             excipients or any other NSAIDs (Non-Steroid Anti-Inflammatory Drug)&#xD;
&#xD;
          -  A history of gastrointestinal ulcer, perforation or bleeding&#xD;
&#xD;
          -  A history of cerebrovascular bleeding or any other bleeding disorder&#xD;
&#xD;
          -  Women of childbearing potential not using adequate contraception (e.g, intrauterine&#xD;
             device, contraceptive pills, Depo-Provera® implant, barrier device) for at least 3&#xD;
             months prior to, and for the duration of trial participation. It should be noted that&#xD;
             NSAIDs may interfere with the effectiveness of intrauterine devices&#xD;
&#xD;
          -  History of bronchial asthma&#xD;
&#xD;
          -  Use of any medications that might influence the results of the trial&#xD;
&#xD;
          -  Use of anticoagulants, including warfarin, heparin, ticlopidine, clopidogrel or&#xD;
             aspirin&#xD;
&#xD;
          -  Any laboratory value outside the normal range that is considered clinically&#xD;
             significant by the investigator. In addition, subjects with the following specific&#xD;
             laboratory values will not be allowed:&#xD;
&#xD;
               -  A serum creatinine concentration at baseline &gt; 1.5 mg/dl&#xD;
&#xD;
               -  SGOT (serum glutamic-oxaloacetic transaminase) or SGPT (serum glutamic-pyruvic&#xD;
                  transaminase) liver enzymes results at baseline &gt; 1.5 times the upper limit of&#xD;
                  normal&#xD;
&#xD;
               -  A hemoglobin concentration &lt; 10.5 g/dl&#xD;
&#xD;
               -  A white cell count &lt; 3500/mm³&#xD;
&#xD;
               -  A platelet &lt; 100,000/mm³ or a documented abnormal bleeding time, platelet&#xD;
                  aggregation, thromboxane B2 synthesis, thromboplastin time (PT) or activated&#xD;
                  partial thromboplastin time (APTT)&#xD;
&#xD;
          -  Inability to refrain from smoking on testing days&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within 30 days of entering&#xD;
             the trial&#xD;
&#xD;
          -  Subjects with increased keloid formation&#xD;
&#xD;
          -  Previous surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Participation in excessive physical activities (≤ 5 days prior to administration)&#xD;
&#xD;
          -  Current drug or alcohol abuse&#xD;
&#xD;
          -  Small or difficult to locate arm veins that would impair the clinician's ability to&#xD;
             draw blood samples&#xD;
&#xD;
          -  Homeopathic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.236_U01-3198.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

